Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.
ICAP at Columbia University, New York, New York, United States of America.
PLoS One. 2023 Jun 26;18(6):e0275560. doi: 10.1371/journal.pone.0275560. eCollection 2023.
BACKGROUND: We examined the epidemiology and transmission potential of HIV population viral load (VL) in 12 sub-Saharan African countries. METHODS: We analyzed data from Population-based HIV Impact Assessments (PHIAs), large national household-based surveys conducted between 2015 and 2019 in Cameroon, Cote d'Ivoire, Eswatini, Kenya, Lesotho, Malawi, Namibia, Rwanda, Tanzania, Uganda, Zambia, and Zimbabwe. Blood-based biomarkers included HIV serology, recency of HIV infection, and VL. We estimated the number of people living with HIV (PLHIV) with suppressed viral load (<1,000 HIV-1 RNA copies/mL) and with unsuppressed viral load (viremic), the prevalence of unsuppressed HIV (population viremia), sex-specific HIV transmission ratios (number female incident HIV-1 infections/number unsuppressed male PLHIV per 100 persons-years [PY] and vice versa) and examined correlations between a variety of VL metrics and incident HIV. Country sample sizes ranged from 10,016 (Eswatini) to 30,637 (Rwanda); estimates were weighted and restricted to participants 15 years and older. RESULTS: The proportion of female PLHIV with viral suppression was higher than that among males in all countries, however, the number of unsuppressed females outnumbered that of unsuppressed males in all countries due to higher overall female HIV prevalence, with ratios ranging from 1.08 to 2.10 (median: 1.43). The spatial distribution of HIV seroprevalence, viremia prevalence, and number of unsuppressed adults often differed substantially within the same countries. The 1% and 5% of PLHIV with the highest VL on average accounted for 34% and 66%, respectively, of countries' total VL. HIV transmission ratios varied widely across countries and were higher for male-to-female (range: 2.3-28.3/100 PY) than for female-to-male transmission (range: 1.5-10.6/100 PY). In all countries mean log10 VL among unsuppressed males was higher than that among females. Correlations between VL measures and incident HIV varied, were weaker for VL metrics among females compared to males and were strongest for the number of unsuppressed PLHIV per 100 HIV-negative adults (R2 = 0.92). CONCLUSIONS: Despite higher proportions of viral suppression, female unsuppressed PLHIV outnumbered males in all countries examined. Unsuppressed male PLHIV have consistently higher VL and a higher risk of transmitting HIV than females. Just 5% of PLHIV account for almost two-thirds of countries' total VL. Population-level VL metrics help monitor the epidemic and highlight key programmatic gaps in these African countries.
背景:我们研究了 12 个撒哈拉以南非洲国家 HIV 人群病毒载量(VL)的流行病学和传播潜力。
方法:我们分析了 2015 年至 2019 年期间在喀麦隆、科特迪瓦、斯威士兰、肯尼亚、莱索托、马拉维、纳米比亚、卢旺达、坦桑尼亚、乌干达、赞比亚和津巴布韦进行的基于人群的 HIV 影响评估(PHIA)大型全国家庭调查的数据。基于血液的生物标志物包括 HIV 血清学、HIV 感染近期情况和 VL。我们估计了具有抑制病毒载量(<1,000 HIV-1 RNA 拷贝/ml)和未抑制病毒载量(病毒血症)的 HIV 感染者人数、未抑制 HIV 的流行率(人群病毒血症)、特定性别 HIV 传播比例(每 100 人年[PY]女性新发 HIV-1 感染人数/未抑制男性 PLHIV 人数和反之亦然),并检查了各种 VL 指标与新发 HIV 之间的相关性。各国的样本量范围为 10,016(斯威士兰)至 30,637(卢旺达);估计值经过加权处理,仅限于 15 岁及以上的参与者。
结果:在所有国家中,女性 PLHIV 的病毒抑制比例均高于男性,但由于总体女性 HIV 流行率较高,所有国家的未抑制女性人数均多于未抑制男性,比例范围为 1.08 至 2.10(中位数:1.43)。HIV 血清阳性率、病毒血症流行率和未抑制成年人数量的空间分布在同一国家内往往存在很大差异。平均而言,VL 最高的 PLHIV 的 1%和 5%分别占各国总 VL 的 34%和 66%。各国之间的 HIV 传播比例差异很大,男性到女性的传播比例(范围:2.3-28.3/100 PY)高于女性到男性的传播比例(范围:1.5-10.6/100 PY)。在所有国家中,未抑制男性的平均 log10 VL 均高于女性。VL 测量值与新发 HIV 之间的相关性存在差异,女性的相关性比男性弱,与每 100 名 HIV 阴性成年人中未抑制的 PLHIV 数量的相关性最强(R2=0.92)。
结论:尽管病毒抑制比例较高,但在所有检查的国家中,女性未抑制 PLHIV 的人数均多于男性。未抑制的男性 PLHIV 的 VL 始终高于女性,传播 HIV 的风险也高于女性。仅 5%的 PLHIV 就占各国总 VL 的近三分之二。人群水平的 VL 指标有助于监测疫情,并突出了这些非洲国家在方案层面上的关键差距。
Front Public Health. 2025-7-16
J Int AIDS Soc. 2025-6
Trop Med Infect Dis. 2025-1-16
S Afr J Infect Dis. 2024-9-25
J Acquir Immune Defic Syndr. 2021-8-1
J Acquir Immune Defic Syndr. 2021-8-1
J Acquir Immune Defic Syndr. 2019-10-1
MMWR Morb Mortal Wkly Rep. 2019-3-22
N Engl J Med. 2018-5-17
Sci Transl Med. 2017-12-13